Tiantan Biology (600161.SH): Affiliated companies obtained approval notices for drug supplementation applications and passed drug GMP compliance checks
Gelonghui, April 10 | Tiantan Biology (600161.SH) announced that Chengdu Rongsheng Pharmaceutical Co., Ltd. recently received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. The “human fibrinogen” developed by Chengdu Rongsheng complies with the relevant requirements for drug registration. At the same time, Chengdu Rongsheng's relevant production site has passed the drug GMP compliance inspection and obtained the “Drug GMP Site Inspection Results Notice” issued by the Sichuan Drug Administration. Chengdu Rongsheng has obtained the “Human Fibrinogen [Specification: 0.5g (25m1) /bottle]” drug supplement application approval
Liberal Arts Biotech (300294.SZ): No business-level cooperation with Tiantan Biotech
Gelonghui March 13 | Liberal Arts Biotech (300294.SZ) said on the investor interactive platform that the company has no business-level cooperation with Tiantan Biotech. The company has always followed industry benchmarks as an example.
Guosheng Securities: Supply and demand resonate and state-owned capital enters a new development cycle in the blood products industry
The supply and demand for blood products continues to expand, and the nearly 60 billion market still has room for growth.
Tiantan Biology (600161.SH): Affiliated company terminates clinical trials of drugs
Gelonghui, January 31 | Tiantan Biology (600161.SH) announced that the “intravenous cytomegalovirus human immunoglobulin (pH4)” developed by Chengdu Rongsheng Pharmaceutical Co., Ltd. is undergoing phase III clinical trial research. After comprehensive evaluation, the company decided to discontinue phase III clinical trial research and subsequent development of this drug. Intravenous cytomegalovirus human immunoglobulin (pH4) is a product independently developed by the company. It is mainly used to treat cytomegalovirus (CMV) emia and related diseases in immunodeficiency patients such as hematopoietic stem cell transplantation. Phase III clinical trials are ongoing. Based on domestic allogeneic hematopoietic stem cells
Dayao Plasma Station belonging to Tiantan Biology (600161.SH) obtained a single plasma collection license
Tiantan Biology (600161.SH) issued an announcement. Sinopharm Group Shanghai Blood Products Co., Ltd., which belongs to the company, is on Dayao...
Tiantan Biotech (600161.SH)'s net profit of 1.03 billion yuan in 2023 increased 25.23% year-on-year
According to Zhitong Finance App News, Tiantan Biotech (600161.SH) disclosed the 2023 annual performance report. During the reporting period, the company achieved total operating revenue of 5.182 billion yuan, an increase of 21.59% over the previous year (after adjustment, same below); net profit attributable to shareholders of listed companies was 1.03 billion yuan, an increase of 25.23% over the previous year. The increase in performance was mainly due to the continued increase in sales revenue due to the increase in product sales in 2023.
Tiantan Biology (600161.SH): The affiliated company plans to invest 30.3 million yuan to build the Lingao Plasma Station project
Gelonghui, December 25 | Tiantan Biology (600161.SH) announced that the board of directors approved the construction project of Sinopharm Group Wuhan Biopharmaceutical Co., Ltd. Lingao Wusheng Single Plasma Collection Co., Ltd. (“Lingao Plasma Station”), which belongs to the company, with a total investment of 30.3 million yuan. The project was funded by Lingao Pulp Station itself.
Tiantan Biology (600161.SH): Affiliated Shanghai Blood Systems plans to invest 25 million yuan to increase the registered capital of Yiliang Pulp Station
On December 25, Gelonghui Biotech (600161.SH) announced that the company's Shanghai Blood System fully invested 25 million yuan to increase the registered capital of Yiliang Pulp Station. After the capital increase was completed, the registered capital of Yiliang Pulp Station increased from 15 million yuan to 40 million yuan, and Shanghai Blood Systems holds 100% of the shares. The capital increase was funded by Shanghai Blood Products itself.
Tiantan Biology (600161.SH): Yiliang Pulp Station plans to purchase commercial premises for the pulp station
Gelonghui, December 25 | Tiantan Biology (600161.SH) announced that the board of directors agreed that Sinopharm Group Shanghai Blood Products Co., Ltd., Yiliang County Shangsheng Single Plasma Collection Co., Ltd. (“Yiliang Plasma Station”), which belongs to the company, will purchase business premises for the plasma station.
Tiantan Biology (600161.SH): Injecting recombinant human coagulation factor VIII-Fc fusion protein obtained a drug clinical trial approval notice
Gelonghui, December 22|Tiantan Biotech (600161.SH) announced that recently, Chengdu Rongsheng Pharmaceutical Co., Ltd., a subsidiary of Beijing Tiantan Biological Products Co., Ltd., obtained the “Notice of Approval of Drug Clinical Trials” issued by the State Drug Administration, agreeing that Chengdu Rongsheng will conduct a clinical trial of “injectable recombinant human coagulation factor-FC fusion protein” according to the submitted plan.
Guotai Junan Blood Products 24-year Strategy: Resonance between supply and demand, a new round of growth cycle is about to begin
Production and sales continue to be strong, and there is no room for growth
Tiantan Biology (600161.SH): Guizhou Blood System plans to conduct clinical trials of “human prothrombin complex”
Gelonghui (600161.SH) announced on December 19|Tiantan Biology () announced that Guizhou Blood Products Co., Ltd. (known as “Guizhou Blood”), which belongs to the company, has obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, agreeing to Guizhou Blood to carry out clinical trials of the “human prothrombin complex”. This product is mainly used to treat congenital and acquired coagulation factors II, VII, IX and X deficiencies (individual or combined defects), including: 1. Coagulation factor II, VII, IX and X deficiency, including hemophilia B; 2. Anticoagulant overdose, vitamin K deficiency; 3. Due to liver
Tiantan Biotech (600161.SH): Affiliated companies won the “High-tech Enterprise Certificate” again
Gelonghui November 29丨Tiantan Biotech (600161.SH) announced that Chengdu Rongsheng Pharmaceutical Co., Ltd., which belongs to it, recently received the “High-tech Enterprise Certificate” jointly issued by the Sichuan Provincial Department of Science and Technology, the Sichuan Provincial Department of Finance, and the Sichuan Provincial Taxation Bureau of the State Administration of Taxation. The certification time: October 16, 2023, is valid for three years.
Tiantan Biotech (600161.SH): Zhang Yi resigns as financial director
Tiantan Biotech (600161.SH) issued an announcement. The company's board of directors received a written message from Mr. Zhang Yi, the company's financial director...
Everbright Securities: The expansion of both supply and demand in the blood products industry is expected to usher in a golden period of development
As the supply capacity of raw plasma continues to increase, product sales in the blood products industry are expected to benefit from increased demand and ushered in a golden period of development.
Tiantan Biology (600161.SH): Proposed adjustment of the Shidian Plasma Station Single Plasma Collection Business Housing Construction Project
Gelonghui November 10 | Tiantan Biology (600161.SH) announced that the board of directors agreed that Shidian County Shangsheng Plasma Collection Co., Ltd. (“Shidian Plasma Station” for short) of the company, Sinopharm Group Shanghai Blood Products Co., Ltd., will be adjusted to a rental housing renovation single plasma collection business housing construction project, with a total investment of 9.9707 million yuan. The project was funded by Shidian Pulp Station itself.
Tiantan Biotech (600161.SH): Affiliated company plans to donate 1 million yuan to the Jingzhou Red Cross
Gelonghui November 10丨Tiantan Biotech (600161.SH) announced that the board of directors agreed that the company's Sinopharm Group Wuhan Biopharmaceutical Co., Ltd. would donate 1 million yuan to the Jingzhou Red Cross.
Tiantan Biotech (600161.SH): Chengdu Rongsheng terminates custody of Guangxi Guanfeng and relinquishes priority share purchase rights
Gelonghui November 10丨Tiantan Biotech (600161.SH) announced that the board of directors agreed that Chengdu Rongsheng Pharmaceutical Co., Ltd., to which the company belongs, terminate the “Custody Agreement between Guangxi Guanfeng Biological Products Co., Ltd. and Chengdu Rongsheng Pharmaceutical Co., Ltd.” signed with Guangxi Guanfeng Biological Products Co., Ltd. and its supplementary agreement; it was agreed that Chengdu Rongsheng would relinquish the priority purchase rights of 95% of Guangxi Guanfeng's shares. It was agreed that Chengdu Rongsheng and Guangxi Guanfeng, its shareholders and other relevant parties would make specific negotiations to handle the aforementioned matters.
[Instant Analysis of BT Financial Report] Tiantan Biotech 2023 Third Quarter Report: Net profit increased significantly, cash flow performance was impressive
This financial report was announced: 2023-10-25 17:58:51 Tiantan Biology (stock code: 600161) is a company focusing on R&D, production and sales of blood products. The company's main products include blood products such as human blood albumin, immunoglobulins, and coagulation factors, which are widely used in the treatment of diseases such as blood loss, trauma, burns, cerebral edema, cirrhosis, nephropathy, hypoproteinemia, and neonatal hyperbilirubinemia. The company uses healthy human plasma and genetic recombinant technology for R&D and production to ensure product quality and safety. From the perspective of assets and liabilities, Tiantan Biotech 2023
Tiantan Biotech (600161.SH) released third-quarter results, net profit of 321 million yuan, an increase of 48.49% over the previous year
Tiantan Biology (600161.SH) released its report for the third quarter of 2023, with the company's revenue of 1,331 billion dollars...
No Data